Captor Therapeutics Spolka Akcyjna

WSE:CTX Stock Report

Market Cap: zł452.2m

Captor Therapeutics Spolka Akcyjna Valuation

Is CTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate CTX's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate CTX's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTX?

Key metric: As CTX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CTX. This is calculated by dividing CTX's market cap by their current book value.
What is CTX's PB Ratio?
PB Ratio13.6x
Bookzł33.27m
Market Capzł452.25m

Price to Book Ratio vs Peers

How does CTX's PB Ratio compare to its peers?

The above table shows the PB ratio for CTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8.6x
BIO BIOTON
0.6xn/azł357.2m
BCX Bioceltix
15x13.03%zł403.8m
RDG Read-Gene
16.3xn/azł62.5m
GEN Genomed Spólka Akcyjna
2.5xn/azł34.9m
CTX Captor Therapeutics Spolka Akcyjna
13.6x91.01%zł452.2m

Price-To-Book vs Peers: CTX is expensive based on its Price-To-Book Ratio (13.6x) compared to the peer average (8.6x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does CTX's PB Ratio compare vs other companies in the European Biotechs Industry?

29 CompaniesPrice / BookEstimated GrowthMarket Cap
CTX 13.6xIndustry Avg. 2.9xNo. of Companies29PB01.63.24.86.48+
29 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CTX is expensive based on its Price-To-Book Ratio (13.6x) compared to the European Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is CTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio13.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CTX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł81.80
zł86.83
+6.15%
20.40%zł110.00zł67.00n/a3
Apr ’27zł80.80
zł86.83
+7.47%
20.40%zł110.00zł67.00n/a3
Mar ’27zł82.00
zł85.17
+3.86%
18.27%zł105.00zł67.00n/a3
Feb ’27zł76.60
zł98.13
+28.11%
23.57%zł122.40zł67.00n/a3
Jan ’27zł72.00
zł105.80
+46.94%
26.02%zł128.00zł67.00n/a3
Dec ’26zł67.80
zł105.80
+56.05%
26.02%zł128.00zł67.00n/a3
Nov ’26zł48.30
zł99.47
+105.94%
36.66%zł128.00zł48.00n/a3
Oct ’26zł40.00
zł99.47
+148.67%
36.66%zł128.00zł48.00n/a3
Sep ’26zł40.40
zł99.47
+146.20%
36.66%zł128.00zł48.00n/a3
Aug ’26zł39.20
zł99.47
+153.74%
36.66%zł128.00zł48.00n/a3
Jul ’26zł35.00
zł99.47
+184.19%
36.66%zł128.00zł48.00n/a3
Jun ’26zł33.40
zł120.13
+259.68%
6.26%zł128.00zł110.00n/a3
May ’26zł31.70
zł120.13
+278.97%
6.26%zł128.00zł110.00n/a3
Apr ’26zł40.50
zł120.13
+196.63%
6.26%zł128.00zł110.00zł80.803
Mar ’26zł47.40
zł120.13
+153.45%
6.26%zł128.00zł110.00zł82.003
Feb ’26zł52.00
zł120.13
+131.03%
6.26%zł128.00zł110.00zł76.603
Jan ’26zł42.30
zł120.13
+184.00%
6.26%zł128.00zł110.00zł72.003
Dec ’25zł47.40
zł120.13
+153.45%
6.26%zł128.00zł110.00zł67.803
Nov ’25zł69.00
zł120.50
+74.64%
8.71%zł131.00zł110.00zł48.302
Oct ’25zł75.60
zł120.50
+59.39%
8.71%zł131.00zł110.00zł40.002
Sep ’25zł76.40
zł115.00
+50.52%
4.35%zł120.00zł110.00zł40.402
Aug ’25zł83.00
zł115.00
+38.55%
4.35%zł120.00zł110.00zł39.202
Jul ’25zł76.80
zł115.00
+49.74%
4.35%zł120.00zł110.00zł35.002
Jun ’25zł73.00
zł115.00
+57.53%
4.35%zł120.00zł110.00zł33.402
May ’25zł80.00
zł115.00
+43.75%
4.35%zł120.00zł110.00zł31.702
Apr ’25zł63.00
zł115.00
+82.54%
4.35%zł120.00zł110.00zł40.502
zł86.83
Fair Value
5.8% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 04:52
End of Day Share Price 2026/04/20 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Captor Therapeutics Spolka Akcyjna is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Marcin NowakIpopema Securities S.A.